In the primary prostate tumour there is progressive loss of dystroglycan function through a combination of altered glycosylation of both α- and β-dystroglycan13 and a concomitant loss of β-dystroglycan protein through a series of proteolytic events that 1st remove the extracellular domain and then the ICD13. This evidence concerns the gene DAG1 and prostate neoplasm.